Money
Filter News
Found 83,198 articles
-
Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
1/3/2024
Homology Medicines, Inc. announced that it received notification from The Nasdaq Stock Market LLC on December 29, 2023 indicating that, for the last thirty consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Global Select Market ).
-
Sail Biomedicines Receives Grants to Fight Malaria by Developing a New Class of RNA Medicines
1/3/2024
Sail Biomedicines, Inc. announced that the Company has received two grants from the Bill & Melinda Gates Foundation to advance Sail’s first-in-category Endless RNA™ platform to develop secreted monoclonal antibodies and vaccines for malaria.
-
Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenues
1/3/2024
Profound Medical Corp. announced preliminary unaudited revenues for the fourth quarter and full year 2023, and provided an update on the progress it is making with the commercialization of TULSA-PRO® in the United States.
-
Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)
1/3/2024
Eterna Therapeutics Inc. announced that Eterna’s Board of Directors granted a non-qualified stock option to purchase 1,685,218 shares of Eterna’s common stock to its new President and Chief Executive Officer, Sanjeev Luther, effective January 1, 2024, the first date of his employment.
-
Keros Therapeutics Announces Proposed Public Offering of Common Stock - Jan 03, 2024
1/3/2024
Keros Therapeutics, Inc. announced the launch of a proposed underwritten public offering of $120.0 million of shares of its common stock.
-
Fortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
1/3/2024
Fortress Biotech, Inc. announced the closing of its previously announced registered direct offering.
-
InFlectis BioScience Awarded $943,000 Grant from the ALS Association to Advance Ongoing ALS Clinical Trial with the Support of IRCCS Carlo Besta Neurological Institute
1/3/2024
InFlectis BioScience, a pioneer in developing first-in-class therapies for neuromuscular diseases, announced that it has been awarded a $943,000 grant to support recruitment and to investigate biomarkers in its Phase 2 clinical trial in patients with bulbar-onset ALS (NCT05508074).
-
Remix Therapeutics Closes $60 Million Financing to Advance REM-422, Pipeline of Small Molecule Therapies Designed to Reprogram RNA Processing to Treat Disease
1/3/2024
Remix Therapeutics (Remix) today announced the close of a $60 million financing led by The Column Group.
-
Nalu Medical, Inc. Announces $65 Million Equity Financing to Advance Treatment for Chronic Neuropathic Pain
1/3/2024
Nalu Medical Inc. (Nalu), a private company focused on innovative, minimally invasive, and non-opioid solutions for chronic neuropathic pain, announced today the closing of a $65 million equity financing.
-
Verona Pharma has been given a leg up from two financial firms, Oxford Finance and Hercules Capital, securing a debt financing facility to support the potential launch of its COPD drug candidate ensifentrine.
-
Trading cash for single-digit royalties on products, the deal provides ImmunityBio with the cash it’ll need to potentially commercialize its bladder cancer drug, if approved. The PDUFA date is April 23, 2024.
-
Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jan 02, 2024
1/2/2024
Alimera Sciences, Inc. announced that Elliot Maltz, C.P.A., has been named Chief Financial Officer effective immediately.
-
NovAccess Global Announces $10.7 Million Financing
1/2/2024
NovAccess Global Inc., a biomedical company developing novel immunotherapies for brain tumor patients, announced it entered into a securities purchase agreement with an affiliate of Sumner Global LLC for a total financing of $10.7 million.
-
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2024
1/2/2024
Johnson & Johnson announced that its Board of Directors has declared a cash dividend for the first quarter of 2024 of $1.19 per share on the company’s common stock.
-
Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing
1/2/2024
Akari Therapeutics, Plc announced that it closed a private placement financing with existing investors, Akari Chairman Dr. Ray Prudo and Director Samir R. Patel, M.D., on December 29, 2023, resulting in gross proceeds of approximately $2 million.
-
Enavate Sciences Backs Graviton Bioscience in Financing Round to Advance Development of Selective ROCK2 Inhibitors
1/2/2024
Graviton Bioscience announced completion of financing from Enavate Sciences, a portfolio company of Patient Square Capital.
-
Jasper Therapeutics, Inc. Announces Reverse Stock Split - Jan 02, 2024
1/2/2024
Jasper Therapeutics, Inc. announced that it will effect a 1-for-10 reverse stock split of its issued and outstanding voting common stock that will become effective at 12:01 a.m. Eastern Time on Thursday, January 4, 2024.
-
Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024
1/2/2024
Seelos Therapeutics, Inc. announced that Institutional Shareholder Services, a leading independent proxy voting and corporate governance advisory firm, recommends Seelos stockholders vote "FOR" all proposals at the Special Meeting of Stockholders, including management's proposal to increase the number of authorized shares of common stock.
-
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - Jan 02, 2024
1/2/2024
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, announced the approval of an inducement award to one new employee, Rebecca Nolan-Olson, who is joining Oncternal as Safety Manager.
-
SomaLogic Urges Stockholders to Maximize Value of Their Investment by Voting "FOR" Pending Merger with Standard BioTools
1/2/2024
SomaLogic, Inc., a leader in proteomics technology, sent the following open letter to stockholders urging them to vote "FOR" the value maximizing transaction with Standard BioTools.